Compare TNC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNC | CAPR |
|---|---|---|
| Founded | 1870 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1994 | 2011 |
| Metric | TNC | CAPR |
|---|---|---|
| Price | $69.10 | $30.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $79.00 | $44.63 |
| AVG Volume (30 Days) | 294.8K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,137,600,000.00 | N/A |
| Revenue This Year | $5.44 | N/A |
| Revenue Next Year | $5.28 | $35.83 |
| P/E Ratio | $28.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $60.18 | $4.30 |
| 52 Week High | $85.91 | $40.37 |
| Indicator | TNC | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 54.68 |
| Support Level | $68.77 | $25.33 |
| Resistance Level | $84.24 | $36.49 |
| Average True Range (ATR) | 2.17 | 1.96 |
| MACD | 0.86 | -0.29 |
| Stochastic Oscillator | 91.78 | 50.91 |
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.